Cite

    Short, N. J., Kantarjian, H., Jabbour, E., Cortes, J. E., Thomas, D. A., Rytting, M. E., Daver, N., Alvarado, Y., Konopleva, M., Kebriaei, P., Wierda, W. G., DiNardo, C. D., Bivins, C., McCue, D., Richie, M. A., & Ravandi, F. (2018). a phase I study of moxetumomab pasudotox in adults with relapsed or refractory B‐cell acute lymphoblastic leukaemia. British journal of haematology, 182, 442–444. http://access.bl.uk/ark:/81055/vdc_100066550386.0x000061